1. Home
  2. BFRG vs SYBX Comparison

BFRG vs SYBX Comparison

Compare BFRG & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bullfrog AI Holdings Inc.

BFRG

Bullfrog AI Holdings Inc.

N/A

Current Price

$1.00

Market Cap

13.1M

Sector

Technology

ML Signal

N/A

Logo Synlogic Inc.

SYBX

Synlogic Inc.

N/A

Current Price

$1.10

Market Cap

15.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BFRG
SYBX
Founded
2017
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.1M
15.2M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
BFRG
SYBX
Price
$1.00
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
65.3K
69.4K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$116,670.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.90
52 Week High
$4.84
$1.96

Technical Indicators

Market Signals
Indicator
BFRG
SYBX
Relative Strength Index (RSI) 41.06 30.44
Support Level $1.10 $1.05
Resistance Level $1.21 $1.20
Average True Range (ATR) 0.07 0.09
MACD 0.01 -0.01
Stochastic Oscillator 13.97 16.22

Price Performance

Historical Comparison
BFRG
SYBX

About BFRG Bullfrog AI Holdings Inc.

Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: